In this TNBC population, tumor PIK3CA mutations, excluding CNAs, had a prevalence of 13.5%, which aligns with previous findings that show PIK3CA is frequently mutated in breast cancer [39, 40] and is potentially an actionable target in the advanced setting [41]. This evidence concerns the gene PIK3CA and neoplasm.